



Prior Authorization

Oncology – Lynparza™ (olaparib capsules and tablets)

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	3
Background.....	3
References	4
Revision History	5

Product Identifier(s)

49972

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Cigna covers olaparib (Lynparza™) as medically necessary when the following criteria are met for FDA Indications or Other Uses with Supportive Evidence:

Prior Authorization is recommended for prescription benefit coverage of Lynparza. All approvals are provided for 3 years in duration.

FDA Indication(s)

1. **Breast Cancer.** Approve for 3 years if the individual meets the following criteria (A, B, C, and D):
 - A) Individual is ≥ 18 years of age; AND
 - B) Individual has metastatic, germline *BRCA* mutation-positive breast cancer; AND
 - C) Individual meets ONE of the following criteria (i or ii):
 - i. Individual meets BOTH of the following criteria (a and b):
 - a) Individual has hormone receptor positive (HR+) [i.e., estrogen receptor positive {ER+} and/or progesterone receptor positive {PR+}] disease; AND
 - b) Individual meets ONE of the following criteria (1 or 2):

- (1) Individual has been treated with prior endocrine therapy; OR
- (2) Individual is considered inappropriate for endocrine therapy; OR
- ii. Individual has triple negative disease (i.e., ER-negative, PR-negative, and HER2-negative); AND
- D) Individual has been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

2. Ovarian Cancer – Treatment.

- A) Initial Therapy. Approve for 3 years if the individual meets the following criteria (i, ii, and iii):
 - i. Individual is ≥ 18 years of age; AND
 - ii. Individual has a germline *BRCA*-mutation as confirmed by an approved test; AND
 - iii. Individual has progressed on three or more prior lines of chemotherapy.
- B) Individual is Currently Receiving Lynparza. Approve for 3 years if the individual has a *BRCA* mutation (germline) as confirmed by an approved test.

3. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer – Maintenance, Monotherapy. Approve for 3 years if the individual meets the following criteria (A and B):

- A) Individual is ≥ 18 years of age; AND
- B) Individual meets ONE of the following (i or ii):
 - i. Individual meets both of the following criteria for first-line maintenance therapy (a and b):
 - a) Individual has a germline or somatic *BRCA* mutation-positive disease as confirmed by an approved test; AND
 - b) Individual is in complete or partial response to first-line platinum-based chemotherapy regimen; OR

Note: Examples are carboplatin with paclitaxel, carboplatin with doxorubicin, docetaxel with carboplatin.
 - ii. Individual is in complete or partial response after at least two platinum-based chemotherapy regimens.

Note: Examples of platinum-based chemotherapy are carboplatin with gemcitabine, carboplatin with paclitaxel, cisplatin with gemcitabine.

4. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer – Maintenance, Combination Therapy.

Approve for 3 years if the individual meets one of the following criteria (A, B, C, and D):

- A) Individual is ≥ 18 years of age; AND
- B) The medication is used in combination with bevacizumab; AND
- C) Individual has homologous recombination deficiency (HRD)-positive disease as confirmed by an approved test.

Note: HRD-positive disease includes individuals with *BRCA* mutation-positive disease; AND
- D) Individual is in complete or partial response to first-line platinum-based chemotherapy regimen. Note: Examples of chemotherapy regimens are carboplatin with paclitaxel, carboplatin with doxorubicin, docetaxel with carboplatin.

5. Pancreatic Cancer – Maintenance Therapy. Approve for 3 years if the individual meets the following criteria (A, B, and C):

- A) Individual is ≥ 18 years of age; AND
- B) Individual has a germline *BRCA* mutation-positive metastatic disease; AND
- C) The disease has not progressed on at least 16 weeks of treatment with a first-line platinum-based chemotherapy regimen.

6. Prostate Cancer – Castration-Resistant. Approve for 3 years if the individual meets the following criteria (A, B, C, D, E, and F):

- A) Individual is ≥ 18 years of age; AND
- B) Individual has metastatic disease; AND
- C) Individual meets one of the following criteria (i or ii):
 - i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog; OR

Note: Examples are Lupron (leuprolide for injection), Lupron Depot (leuprolide acetate for depot suspension), Trelstar (triptorelin pamoate for injectable suspension), Zoladex (goserelin acetate

implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix for injection), Orgovyx (relugolix tablets).

ii. Individual has had a bilateral orchiectomy; AND

D) Individual has germline or somatic homologous recombination repair (HRR) gene-mutated disease, as confirmed by an approved test; AND

Note: HRR gene mutations include *BRCA1*, *BRCA2*, *ATM*, *BARD1*, *BRIP1*, *CDK12*, *CHEK1*, *CHEK2*, *FANCL*, *PALB2*, *RAD51B*, *RAD51C*, *RAD51D*, or *RAD54L*.

E) Individual does not have a *PPP2R2A* mutation; AND

F) Individual has been previously treated with abiraterone or Xtandi (enzalutamide capsules).

Conditions Not Covered

Olaparib (Lynparza™) is considered experimental, investigational or unproven for ANY other use.

Background

Overview

Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor, is indicated for the following:¹

- **Breast cancer**, in adult patients with deleterious or suspected deleterious *gBRCA* mutated, HER2-negative metastatic disease, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.
- **Ovarian cancer, treatment** in adult patients with deleterious or suspected deleterious germline *BRCA* mutated advanced who have been treated with three or more prior lines of chemotherapy.
- **Ovarian cancer, maintenance** treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
- **Ovarian cancer, maintenance** treatment of adult patients with deleterious or suspected deleterious *gBRCA* or somatic *BRCA*-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
- **Ovarian cancer, maintenance treatment in combination** with bevacizumab for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious *BRCA* mutation, and/or genomic instability.
- **Pancreatic adenocarcinoma**, maintenance treatment of adult patients with deleterious or suspected deleterious *gBRCA* mutated metastatic disease, who have not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
- **Prostate cancer**, castration-resistant (CRPC), for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic CRPC (mCRPC) who have progressed following prior treatment with Xtandi (enzalutamide tablets) or abiraterone.

Lynparza tablets and capsules are not interchangeable; they have different dosing and bioavailability. The tablet formulation yields a lower daily pill burden than the capsule formulation.

Guidelines

- **Breast Cancer:** The National Comprehensive Cancer Network (NCCN) breast cancer guidelines (version 1.2021 – January 15, 2021) recommend assessing for germline *BRCA1/2* mutations in all patients with recurrent or metastatic disease to identify candidates for PARP inhibitor therapy.³ Lynparza is noted as one of the preferred single agents for *BRCA 1/2* positive tumors (category 1). It is noted that although Lynparza is FDA-approved for HER2-negative disease, the NCCN panel supports use in any breast cancer subtype with *BRCA1* or *BRCA2* mutation.

- **Ovarian Cancer:** The NCCN guidelines on ovarian cancer (version 2.2020 – January 12, 2021) recommend Lynparza for maintenance therapy after primary treatment in patients who have had a complete or partial response.² Lynparza is recommended for *BRCA* 1/2 mutations (category 1). Lynparza in combination with bevacizumab is recommended if bevacizumab was used as part of primary therapy. This combination is recommended for both *BRCA*1/2 wild-type (or unknown) [category 2A] and for germline/somatic *BRCA*1/2 mutation (category 1) in patients who have achieved a complete or partial response. The guidelines recommend use of Zejula™ (niraparib capsules), Rubraca™ (rucaparib tablets), or Lynparza as maintenance therapy options in patients with platinum-sensitive disease who have completed two or more lines of platinum-based therapy. The guidelines recommend Lynparza as one of the preferred single-agent targeted therapies for patients with deleterious germline *BRCA* mutated advanced (persistent disease or recurrence) ovarian cancer following three or more lines of therapy (category 2A).
- **Pancreatic Cancer:** The NCCN pancreatic adenocarcinoma guidelines (version 1.2021 – October 23, 2020) recommend Lynparza for maintenance therapy after the patient has tried first-line systemic therapy.⁴ It is specifically recommended in patients who have germline *BRCA* 1/2 mutations and who have not had disease progression after at least 4 to 6 months of chemotherapy.
- **Prostate Cancer:** The NCCN prostate cancer guidelines (version 3.2020 – November 17, 2020) recommends Lynparza for HRRm in the second-line setting (category 1), after first-line treatment with Xtandi or abiraterone. In patients who have received first-line docetaxel, Lynparza is a category 2B recommended therapy in the second-line setting for HRRm. In a footnote it is noted that Lynparza is a treatment option for patients with mCRPC and a pathogenic mutation (germline and/or somatic) in a HRR gene (*BRCA1*, *BRCA2*, *ATM*, *BARD1*, *BRIP1*, *CDK12*, *CHEK1*, *CHEK2*, *FANCL*, *PALB2*, *RAD51B*, *RAD51C*, *RAD51D*, or *RAD54L*), who have been treated with androgen receptor-directed therapy. Patients with PPP2R2A mutation in the PROfound trial experienced an unfavorable risk-benefit profile. Therefore, Lynparza is not recommended in patients with a PPP2R2A mutations.

References

1. Lynparza™ capsules [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2020.
2. The NCCN Ovarian Cancer Clinical Practice Guidelines in Oncology (version 2.2020 – January 12, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on February 1, 2021.
3. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 1.2021 – January 15, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on February 1, 2021.
4. The NCCN Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology (version 1.2021 – October 23, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on February 1, 2021.
5. The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (version 3.2020 – November 17, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed February 1, 2021.
6. The NCCN Drugs & Biologics Compendium. © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on February 1, 2021. Search term: olaparib.

Revision History

Type of Revision	Summary of Changes	Review Date
Annual Revision	All indications: Added age criteria of ≥ 18 years. Breast Cancer: Deleted criteria requiring use in HER2-negative disease. The breast cancer guidelines recommend use in any subtype with <i>BRCA</i> mutation. Prostate Cancer – Castration-Resistant: Added Orgovyx as example in Note for GnRH analog.	02/03/2021

BRCA – BReast CAncer; HER2 – Human epidermal growth factor receptor 2; GnRH – Gonadotropin-releasing hormone.

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.